



BMA BIOMEDICALS

Monoclonal Antibody To Human CD120a

Anti human Tumor Necrosis Factor (TNF) - Receptor p55

Monoclonal antibody htr 9 is useful for studying biological effects of TNF-receptor p55 *in vitro*. The antibody inhibits binding of radiolabeled TNF to human cells expressing the p55 TNF receptor. In order to obtain complete inhibition of TNF binding to the cell surface, 10µg/ml of htr-9 are required. htr 9 itself may have an agonistic effect in assays measuring cytotoxicity, fibroblast growth or IL-6 secretion. See also Product T-1412, anti human CD120b (TNF-receptor p75), clone utr 1.

This antibody was produced serum-free, without fetal calf serum.

TECHNICAL AND ANALYTICAL CHARACTERISTICS

Product Number:	T-1409 (Lot 05PO1412)
Clone:	htr 9
Host species, isotype:	Mouse IgG1
Quantity:	200µg
Format:	Affinity purified, lyophilizer Reconstitute by adding 0.5ml distilled water. This stock solution contains 0.4mg/ml IgG, phosphate buffered saline pH 7.2 (PBS), 5mg/ml bovine serum albumin (BSA) as a stabilizer, and 0.05% (v/v) Kathon™ CG as a preservative.
Stability:	Original vial: 1 year at 4° - 8°C from date of purchase. Stock solution and aliquots thereof: 1 year at -20°C. Avoid freeze-thaw cycles.
Applications:	Tested for immunohistochemistry (IHC); has also been described to work in FACS and Western Blots. Approximate working dilution for IHC: Frozen sections: 2-5µg/ml (1:80 - 1:200) Paraffin sections: 20µg/ml (1:20) Please see www.bma.ch for protocols and general
Immunogen:	Recombinant human IL-1Ra
Protein database:	<u>human-P19438</u>

Antigen distribution:

The antigen is produced and secreted by monocytes and macrophages after stimulation with pro-inflammatory cytokines, LPS, and *in vitro* by immunoglobulins coated to surfaces after an induction phase of 4h. *In vitro* the quantity of IL-1ra secreted depends on the dose and type of stimulus.

Specificity:

Human: IL-1 receptor antagonist; negative with human IL-1beta, IL-1 alpha.

Other: negative with mouse IL-1Ra, other species unknown.

Selected references

Towbin, H. et al., J Immunol Meth **170**:125-135 (1994)

Dinarello, C.A. and Thompson, R.C., Immunology Today **12**:404 (1991)

Dinarello, C.A. and Wolff, S.M., New Engl. J. Med. **328**:106 (1993).

For in vitro research only. This product contains Kathon™ CG as a preservative.